Status:
COMPLETED
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Primary Insomnia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
To evaluate the safety and tolerability of gaboxadol in primary insomnia
Detailed Description
To evaluate long-term safety of gaboxadol in healthy adults.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- patients with a diagnosis of primary insomnia
Exclusion
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
September 1 2005
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00209950
Start Date
July 1 2004
End Date
September 1 2005
Last Update
March 30 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Non-US study, principal location:
Regensburg, Germany